Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

60.85
-0.6600-1.07%
Post-market: 60.950.1000+0.16%18:23 EDT
Volume:1.99M
Turnover:121.93M
Market Cap:5.90B
PE:26.02
High:62.13
Open:61.37
Low:60.55
Close:61.51
Loading ...

Evercore ISI Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
28 Feb

Sarepta Therapeutics’ Earnings Call Highlights Record Growth

TIPRANKS
·
28 Feb

Sarepta price target lowered to $210 from $217 at BofA

TIPRANKS
·
27 Feb

Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales

Zacks
·
27 Feb

Cantor Fitzgerald Remains a Buy on Sarepta Therapeutics (SRPT)

TIPRANKS
·
27 Feb

Sarepta Therapeutics Price Target Maintained With a $202.00/Share by Needham

Dow Jones
·
27 Feb

Optimistic Buy Rating for Sarepta Therapeutics Driven by Elevidys Potential and Expanding Pipeline

TIPRANKS
·
27 Feb

Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), MannKind (MNKD)

TIPRANKS
·
27 Feb

Sarepta Therapeutics, Inc. : Deutsche Bank Cuts Target Price to $124 From $136

THOMSON REUTERS
·
27 Feb

Sarepta Therapeutics Inc : Bofa Global Research Cuts Price Objective to $210 From $217

THOMSON REUTERS
·
27 Feb

Sell Recommendation for Sarepta Therapeutics Amid Concerns Over ELEVIDYS Uptake and Coverage Limitations

TIPRANKS
·
27 Feb

Morgan Stanley Lifts Price Target on Sarepta Therapeutics to $196 From $195, Keeps Overweight Rating

MT Newswires Live
·
27 Feb

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Amedisys (AMED) and CSPC Pharmaceutical Group (OtherCHJTF)

TIPRANKS
·
27 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Arcus Biosciences (RCUS) and Certara (CERT)

TIPRANKS
·
27 Feb

U.S. RESEARCH ROUNDUP-Abbvie, Freeport-McMoran, Goldman Sachs

Reuters
·
27 Feb

Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com
·
27 Feb

Sarepta Therapeutics Inc : RBC Cuts Target Price to $161 From $165

THOMSON REUTERS
·
27 Feb

Sarepta Therapeutics Reports Strong 2024 Financial Results

TIPRANKS
·
27 Feb

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
27 Feb

Sarepta Therapeutics: Strong Financial Performance and Strategic Outlook Justify Buy Rating

TIPRANKS
·
27 Feb